Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2014 1
2015 2
2016 2
2017 4
2018 6
2019 9
2020 4
2021 8
2022 7
2023 12
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
Hassan PM, Ali T, Saber E, Asghar A, Delaram D, Mostafa SV, Maryam S, Maryam K, Talieh S, Ali KM, Mohammad P, Fereidoon K, Anahita B, Yury VB, Dagmar GR, Vicente VB, Alireza B, Kazem B. Hassan PM, et al. Among authors: alireza b. Vaccine. 2022 May 3;40(20):2856-2868. doi: 10.1016/j.vaccine.2022.03.066. Epub 2022 Apr 4. Vaccine. 2022. PMID: 35393148 Free PMC article.
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, Khamesipour A, Jalali T, Nakhaeizadeh M, Sharifi H, Mansoori Y, Keramat F, Ghodrati S, Javanian M, Doroud D, Omrani MD, Asadi H, Pouriayevali MH, Ghasemian R, Farshidi H, Pourahmad M, Ghasemzadeh I, Mounesan L, Darvishian M, Mirjalili MR, Toledo-Romani ME, Valenzuela-Silva C, Verez-Bencomo V, Gouya MM, Emadi-Koochak H, Haghdoost AA, Biglari A; Soberana Study Group. Mostafavi E, et al. Among authors: biglari a. JAMA Netw Open. 2023 May 1;6(5):e2310302. doi: 10.1001/jamanetworkopen.2023.10302. JAMA Netw Open. 2023. PMID: 37133864 Free PMC article. Clinical Trial.
Human IL-2Rɑ subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach.
Beig Parikhani A, Bagherzadeh K, Dehghan R, Biglari A, Shokrgozar MA, Riazi Rad F, Zeinali S, Talebkhan Y, Ajdary S, Ahangari Cohan R, Behdani M. Beig Parikhani A, et al. Among authors: biglari a. PLoS One. 2022 Feb 25;17(2):e0264353. doi: 10.1371/journal.pone.0264353. eCollection 2022. PLoS One. 2022. PMID: 35213635 Free PMC article.
Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine.
Farahmand B, Sadat Larijani M, Fotouhi F, Biglari A, Sorouri R, Bagheri Amiri F, Eslamifar A, Jalali T, Salehi-Vaziri M, Banifazl M, Dahmardeh S, Eshratkhah Mohammadnejad A, Bavand A, Tavakoli M, Verez-Bencomo V, Mostafavi E, Noori Daloii H, Ashrafian F, Saberpour M, Ramezani A. Farahmand B, et al. Among authors: biglari a. Heliyon. 2023 Sep 29;9(10):e20555. doi: 10.1016/j.heliyon.2023.e20555. eCollection 2023 Oct. Heliyon. 2023. PMID: 37810803 Free PMC article.
PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals.
Ramezani A, Sorouri R, Haji Maghsoudi S, Dahmardeh S, Doroud D, Sadat Larijani M, Eybpoosh S, Mostafavi E, Olyaeemanesh A, Salehi-Vaziri M, Bavand A, Zarghani G, Moradi L, Ashrafian F, Bagheri Amiri F, Mashayekhi P, Tahmasebi Z, Biglari A. Ramezani A, et al. Among authors: biglari a. Sci Rep. 2023 May 18;13(1):8065. doi: 10.1038/s41598-023-35147-y. Sci Rep. 2023. PMID: 37202438 Free PMC article.
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
Barkhordar M, Chahardouli B, Biglari A, Ahmadvand M, Bahri T, Alaeddini F, Sharifi Aliabadi L, Noorani SS, Bagheri Amiri F, Biglari M, Shemshadi MR, Ghavamzadeh A, Vaezi M. Barkhordar M, et al. Among authors: biglari a. Front Immunol. 2023 Apr 19;14:1169666. doi: 10.3389/fimmu.2023.1169666. eCollection 2023. Front Immunol. 2023. PMID: 37153556 Free PMC article.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Toledo-Romani ME, García-Carmenate M, Verdecia-Sánchez L, Pérez-Rodríguez S, Rodriguez-González M, Valenzuela-Silva C, Paredes-Moreno B, Sanchez-Ramirez B, González-Mugica R, Hernández-Garcia T, Orosa-Vázquez I, Díaz-Hernández M, Pérez-Guevara MT, Enriquez-Puertas J, Noa-Romero E, Palenzuela-Diaz A, Baro-Roman G, Mendoza-Hernández I, Muñoz Y, Gómez-Maceo Y, Santos-Vega BL, Fernandez-Castillo S, Climent-Ruiz Y, Rodríguez-Noda L, Santana-Mederos D, García-Vega Y, Chen GW, Doroud D, Biglari A, Boggiano-Ayo T, Valdés-Balbín Y, Rivera DG, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Toledo-Romani ME, et al. Among authors: biglari a. Med. 2022 Nov 11;3(11):760-773.e5. doi: 10.1016/j.medj.2022.08.001. Epub 2022 Aug 8. Med. 2022. PMID: 35998623 Free PMC article. Clinical Trial.
Corrigendum to 'How Iran responded to expanding need for laboratory services for COVID-19?'.
Salehi-Vaziri M, Arashkia A, Mostafavi E, Jalali T, Pouriayevali MH, Fazlalipour M, Shoja Z, Rohani M, Esmaeili S, Fotouhi F, Baesi K, Maleki A, Nasab SDM, Ahmadi Z, Mohammadi T, Azad-Manjiri S, Nosrati MSS, Tavakoli M, Fereydouni Z, Khakifirouz S, Samiee SM, Biglari A, Azadmanesh K. Salehi-Vaziri M, et al. Among authors: biglari a. Health Policy Technol. 2021 Dec;10(4):100570. doi: 10.1016/j.hlpt.2021.100570. Epub 2021 Oct 27. Health Policy Technol. 2021. PMID: 34722139 Free PMC article.
53 results